2098 related articles for article (PubMed ID: 34636722)
1. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
Elife; 2021 Oct; 10():. PubMed ID: 34636722
[TBL] [Abstract][Full Text] [Related]
2. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
bioRxiv; 2021 Jul; ():. PubMed ID: 34013277
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
4. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
6. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
7. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
8. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
Front Immunol; 2021; 12():737083. PubMed ID: 34539673
[TBL] [Abstract][Full Text] [Related]
9. Distinct T cell responsiveness to different COVID-19 vaccines and cross-reactivity to SARS-CoV-2 variants with age and CMV status.
Brummelman J; Suárez-Hernández S; de Rond L; Bogaard-van Maurik M; Molenaar P; van Wijlen E; Oomen D; Beckers L; Rots NY; van Beek J; Nicolaie MA; van Els CACM; Boer MC; Kaaijk P; Buisman AM; de Wit J
Front Immunol; 2024; 15():1392477. PubMed ID: 38774878
[TBL] [Abstract][Full Text] [Related]
10. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
[TBL] [Abstract][Full Text] [Related]
11. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
12. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.
Tauzin A; Gong SY; Beaudoin-Bussières G; Vézina D; Gasser R; Nault L; Marchitto L; Benlarbi M; Chatterjee D; Nayrac M; Laumaea A; Prévost J; Boutin M; Sannier G; Nicolas A; Bourassa C; Gendron-Lepage G; Medjahed H; Goyette G; Bo Y; Perreault J; Gokool L; Morrisseau C; Arlotto P; Bazin R; Dubé M; De Serres G; Brousseau N; Richard J; Rovito R; Côté M; Tremblay C; Marchetti GC; Duerr R; Martel-Laferrière V; Kaufmann DE; Finzi A
Cell Host Microbe; 2022 Jan; 30(1):97-109.e5. PubMed ID: 34953513
[TBL] [Abstract][Full Text] [Related]
13. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
Elife; 2023 Jan; 12():. PubMed ID: 36692910
[TBL] [Abstract][Full Text] [Related]
14. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
15. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
Elife; 2023 Mar; 12():. PubMed ID: 36975207
[TBL] [Abstract][Full Text] [Related]
16. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination.
Goel RR; Apostolidis SA; Painter MM; Mathew D; Pattekar A; Kuthuru O; Gouma S; Hicks P; Meng W; Rosenfeld AM; Dysinger S; Lundgreen KA; Kuri-Cervantes L; Adamski S; Hicks A; Korte S; Oldridge DA; Baxter AE; Giles JR; Weirick ME; McAllister CM; Dougherty J; Long S; D'Andrea K; Hamilton JT; Betts MR; Luning Prak ET; Bates P; Hensley SE; Greenplate AR; Wherry EJ
Sci Immunol; 2021 Apr; 6(58):. PubMed ID: 33858945
[TBL] [Abstract][Full Text] [Related]
17. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
Front Immunol; 2024; 15():1390022. PubMed ID: 38698851
[TBL] [Abstract][Full Text] [Related]
19. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
Front Immunol; 2021; 12():781280. PubMed ID: 34987509
[TBL] [Abstract][Full Text] [Related]
20. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
